Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy For Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.

Autor: Slomovitz BM; Mount Sinai Medical Center, Miami Beach, FL, USA; and GOG Foundation., Cibula D; Department of Gynecology, Obstetrics and Neonatology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic; and Central and Eastern European Gynecologic Oncology Group (CEEGOG)., Lv W; Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China., Ortaç F; Ankara University School of Medicine, Ankara, Turkey; and Turkish Society of Gynecologic Oncology (TRSGO)., Hietanen S; Turku University Hospital, FICAN West Cancer Centre, Turku, Finland; and Nordic Society of Gynaecological Oncology (NSGO)., Backes F; Division of Gynecologic Oncology, Ohio State University and James Cancer Hospital, Columbus, OH, USA; and GOG Foundation., Kikuchi A; Department of Gynecology, Niigata Cancer Center Hospital, Niigata, Japan., Lorusso D; Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome and Humanitas University, Rozzano (Milan), Italy; and Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO)., Dańska-Bidzińska A; Department of Gynecological Oncology, 2nd Division of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, Poland; and Polish Group of Gynaecological Oncology (PGOG)., Samouëlian V; Gynecologic Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Centre de Recherche du CHUM (CRCHUM), Université de Montréal, Montreal, QC, Canada., Barretina-Ginesta MP; Catalan Institute of Oncology and Girona Biomedical Research Institute, Medical School University of Girona, Girona, Spain; and Spanish Ovarian Cancer Research Group (GEICO)., Vulsteke C; Integrated Cancer Center Ghent, Department of Medical Oncology, AZ Maria Middelares Ghent and Center of Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Antwerp, Belgium; and Belgian and Luxembourg Gynaecological Oncology Group (BGOG)., Lai CH; Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Branch, Chang Gung University, College of Medicine, Taoyuan, Taiwan; Gynecologic Cancer Research Center, Chang Gung Memorial Hospital, Linkou Branch, Taiwan; and Taiwanese Gynecologic Oncology Group (TGOG)., Pothuri B; Department of Obstetrics and Gynecology and Medicine, Division of Gynecologic Oncology, Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA; and GOG Foundation., Zhang Y; Department of Gynecology, Xiangya Hospital, Central South University, Changsha, Hunan, PR China., Magallanes-Maciel M; Centro Oncologico Internacional, Mexico City, Mexico., Amit A; Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Department of Obstetrics and Gynecology, Rambam Health Care Campus, Haifa, Israel; and Israeli Society of Gynecology Oncology (ISGO)., Guarneri V; Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, Padova, Italy; and Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; and Mario Negri Gynecologic Oncology (MaNGO)., Zagouri F; Department of Clinical Therapeutics, Medical School of National and Kapodistrian University of Athens, 'Alexandra' General Hospital of Athens, 115 28 Athens, Greece; and Hellenic Cooperative Oncology Group (HeCOG)., Bell M; Sanford Health, Sioux Falls, SD, USA; and GOG., Welz J; Department of Gynecology and Gynecologic Oncology, Evang. Kliniken Essen-Mitte, Essen, Germany; and German Gynecological Oncology Group (AGO)., Eminowicz G; University College London Hospitals and University College London, London, UK; and National Cancer Research Institute (NCRI)., Hruda M; Department of Gynecology and Obstetrics, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic; and CEEGOG., J Willmott L; The University of Arizona College of Medicine, Phoenix, AZ, USA; Creighton University School of Medicine at Dignity Health St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA; Maricopa Integrated Health System, Phoenix, AZ, USA; Arizona Center for Cancer Care (Virginia Piper Cancer Care Network), Phoenix, AZ, USA; and GOG., Lichfield J; MSD UK, London, United Kingdom., Wang W; MSD China, Shanghai, China., Orlowski R; Merck & Co., Inc., Rahway, NJ, USA., Aktan G; Merck & Co., Inc., Rahway, NJ, USA., Gladieff L; Medical Oncology, Oncopole CLAUDIUS REGAUD, IUCT-Oncopole, Toulouse, France; and National Investigators Group for the Study of Ovarian and Breast Cancers (GINECO)., Van Gorp T; Division of Gynaecological Oncology, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium; and BGOG.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Oct 16, pp. 101200JCO2401887. Date of Electronic Publication: 2024 Oct 16.

Staging karcinomu endometria FIGO 2023 a jeho význam pro klinickou praxi.

Autor: Sehnal, B., Kubecová, M., Hruda, M., Drozenová, J., Halaška, J. M., Havlík, J., Robová, H., Pichlík, T., Grafnetter Regináčová, K., Rob, L.

Publikováno v: Journal of the Czech & Slovak Societies for Oncology / Klinická Onkologie; 2024, Vol. 37 Issue 4, p250-258, 9p

Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.

Autor: Holý P; Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic.; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic., Hlaváč V; Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic.; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic., Šeborová K; Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic.; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic., Šůsová S; Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic.; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic., Tesařová T; Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic.; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic., Rob L; Department of Gynecology and Obstetrics, Third Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic., Hruda M; Department of Gynecology and Obstetrics, Third Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic., Bouda J; Department of Gynecology and Obstetrics, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic., Bartáková A; Department of Gynecology and Obstetrics, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic., Mrhalová M; Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University, Prague, Czech Republic., Kopečková K; Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic., Al Obeed Allah M; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic., Špaček J; University Hospital Hradec Králové, Hradec Kralove, Czech Republic., Sedláková I; University Hospital Hradec Králové, Hradec Kralove, Czech Republic., Souček P; Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic.; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic., Václavíková R; Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic.; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.

Publikováno v: International journal of cancer [Int J Cancer] 2024 Jul 01; Vol. 155 (1), pp. 104-116. Date of Electronic Publication: 2024 Mar 06.

Nový staging karcinomu endometria – FIGO 2023.

Autor: Hruda, M., Sehnal, B., Halaška, M. J., Drozenová, J., Robová, H., Pichlík, T., Rob, L.

Publikováno v: Czech Gynaecology / Česká Gynekologie; 2024, Vol. 89 Issue 2, p120-127, 8p

Infekce lidským papilomavirem (HPV) a gravidita.

Autor: Sehnal, B., Halaška, M. J., Vlk, R., Drochýtek, V., Pichlík, T., Hruda, M., Robová, H., Rob, L., Tachezy, R.

Publikováno v: Epidemiology, Microbiology, Immunology / Epidemiologie, Mikrobiologie, Imunologie; 2024, Vol. 73 Issue 1, p37-50, 14p